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of  consensus  on  this  disorder,  in  Portugal,  inter-hospital  heterogeneity  in  clinical  prac-
tice and  resources  available  have  been  adding  difficulties  in  reaching  a  diagnosis  and  in
making therapeutic  decisions  in  this  group  of  patients.  This  raised  a  need  to  draft  a  doc-
ument expressing  a  national  consensus  for  AATD.  To  this  end,  a  group  of  experts  in  this
field was  created  within  the  Portuguese  Pulmonology  Society  -  Study  group  on  AATD,  in
order to  elaborate  the  current  manuscript.  The  authors  reviewed  the  existing  literature
and provide  here  general  guidance  and  extensive  recommendations  for  the  diagnosis  and
management  of  AATD  that  can  be  adopted  by  Portuguese  clinicians  from  different  areas  of
Medicine.
This article  is  part  of  a  supplement  entitled  ‘‘Portuguese  consensus  document  for  the  mana-
gement of  alpha-1-antitrypsin  deficiency’’  which  is  sponsored  by  Sociedade  Portuguesa  de
Pneumologia.
© 2018  Published  by  Elsevier  España,  S.L.U.  on  behalf  of  Sociedade  Portuguesa  de  Pneumologia.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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LPHA-1-ANTITRYPSIN AND
ATHOPHYSIOLOGY  OF ITS DEFICIENCY
lpha-1-antitrypsin  (AAT)  --  the  major  serine  protease
nhibitor  in  the  serum  --  is  primarily  synthesized  by  hep-
tocytes  and  also  produced  at  lower  concentrations  by
eutrophils,  mononuclear  phagocytes,  and  epithelial  lung
nd  intestine  cells.  Once  secreted  into  the  bloodstream,
AT  weighs  approximately  52  KDa,  is  composed  of  394
mino  acids  and  three  carbohydrate  side  chains  linked  to
sparagine  residues.1,2 Structurally,  this  globular  glycopro-
ein  presents  three  -sheets  (A-C),  nine  -helices  (A-I)  and  a
olvent  exposed  stretch  named  reactive  centre  loop  (RCL).
here,  the  peptide  bond  Met358-Ser359  (P1-P1’)  mimics  a
rotease  substrate  and,  upon  its  cleavage,  AAT  initiates
 major  conformation  rearrangement  that  culminates  in
he  formation  of  a  stable  inhibitor-protease  complex.3--5
lthough  AAT  is  well  established  as  a  potent  inhibitor  of
eutrophil  elastase  in  the  lung,  it  is  also  capable  of  inhibit-
ng  other  proteinases,  such  as  proteinase  3,  kallikreins  7,
atriptase  and  caspase-3.  More  recently,  immunity-related
nd  anti-inflammatory  functions  have  also  been  attributed
o  AAT.1,6
AAT  is  encoded  by  the  SERPINA1  gene  located  in
he  chromosome  14q32.1  region.  This  gene  encompasses
pproximately  14  kb  and  is  organized  into  three  untranslated
xons  (Ia-Ic)  containing  different  tissue-specific  transcrip-
ion  start  sites  and  four  coding  exons  (II-V).7
AAT  deficiency  (AATD)  is  inherited  as  an  autosomal
odominant  condition,  which  is  caused  by  pathogenic  muta-
ions  in  SERPINA1.  There  are  currently  over  120  identified
lleles  that  follow  a  specific  coding  system,  in  which  inher-
ted  AAT  variants  are  classified  between  ‘A’  and  ‘Z’  based  on
heir  migration  in  an  isoelectric  focusing  (IEF)  pH  gradient
‘A’  denotes  the  most  anodal  variants  and  ‘Z’  the  slowest
igrating  alleles  --  see  also  section  3.2.3.1).
AAT  variants  can  be  categorized  into  four  groups8: Normal  variants,  characterized  by  normal  AAT  serum  lev-
els  (20--53  M,  or  80--220  mg/dl  by  nephelometry).
 Deficiency  variants,  characterized  by  AAT  serum  levels
below  20  M,  and,  in  the  case  of  some  alleles  (i.e.  Z),
p
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concomitant  decreased  functional  activity  of  the  AAT
molecule.
 Null  variants  (Q0),  which  are  characterized  by  the  absence
of  circulating  AAT  due  to  either  transcriptional  or  transla-
tional  errors  that  prevent  normal  protein  synthesis.
 Dysfunctional  variants,  which  are  characterized  by  an
abnormal  function  of  AAT  (i.e.  reduced  binding  to  neu-
trophil  elastase,  which  is  the  case  of  F  and  Z  variants,
or  with  altered  inhibitory  activity,  which  is  the  case  of
anti-thrombin  Pittsburgh  variant).9
Normal  alleles  are  present  in  85--90%  of  individuals  and
re  designated  as  M;  therefore,  normal  individuals  reveal
M  genotypes.  On  the  other  hand,  most  prevalent  deficiency
lleles  are  designated  as  S  and  Z.10 The  Z  allele  results  from
 Glu342Lys  substitution  that  causes  the  loss  of  a  crucial  salt
ridge  (Glu342-Lys290)  and  affects  the  stability  of  the  A  -
heet  (breach  and  shutter  domains).3 This  structural  change
s  thought  to  facilitate  the  insertion  of  the  RCL  into  the  shut-
er  of  another  AAT  molecule  prompting  the  accumulation  of
 polymers  in  the  endoplasmic  reticulum  (ER).2 The  S  allele
s  caused  by  a  Glu264Val  replacement  that  also  leads  to  the
isruption  of  a  salt  bridge  (Glu264-Lys387)  linking  an  -helix
o  the  molecule  core.3 The  S  variant  is  also  prone  to  poly-
erization  in  the  ER;  however,  its  rate  is  only  marginal  when
ompared  to  the  Z  allele.1,11,12
PIDEMIOLOGY
pidemiological  studies  show  that  AATD  is  one  of  the  most
revalent  genetic  disorders  in  humans  and  the  most  com-
only  diagnosed  in  adults.  Over  the  past  10-15  years,
iagnosis  of  AATD  has  markedly  improved  as  a  result  of
ncreasing  awareness  and  the  publication  of  international
iagnostic  and  management  evidence-based  recommen-
ations.  Nevertheless,  this  condition  remains  widely  and
ersistently  under-diagnosed  or  misdiagnosed  by  healthcare
roviders.  Even  in  Sweden,  where  AATD  was  first  recognized
nd  reported,  Piitulainen  and  Tanash  stated  recently  that
nly  20%  of  all  expected  cases  of  severe  AATD  in  adults  were
eported  to  the  Swedish  national  registry.13
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Portuguese  consensus  document  for  the  management  of  alp
Despite  scarce  epidemiological  information  on  a  world-
wide  basis,  several  studies  showed  that  AATD  is  relatively
common  among  Europeans  and  its  frequency  can  be  com-
pared  to  that  of  cystic  fibrosis,  which  affects  one  in  every
2000  to  4000  people.14 Nonetheless,  the  study  carried  out
by  de  Serres15 --  which  included  58  countries  worldwide  and
a  total  population  of  approximately  4.4  billion  inhabitants  --
obtained  an  estimate  of  at  least  116  million  carrying  AATD  MS
or  MZ  and  approximately  3.4  million  deficiency  allele  com-
binations  (SS,  SZ,  and  ZZ).  This  study  also  concluded  that
AATD  is  an  inherited  condition  affecting  all  racial  subgroups,
not  just  Europeans  but  rather  several  African  populations,
middle  eastern  Jews  and  Arabs,  and  Asians  as  well.  Blanco
et  al16 carried  out  a  multicentric  study  involving  21  Euro-
pean  countries  in  order  to  estimate  the  number  of  carriers
for  the  two  most  common  deficiency  alleles  (S  and  Z).  This
study  revealed  that  Italy,  Spain,  Germany,  France,  United
Kingdom,  Latvia,  Sweden,  and  Denmark  have  the  highest
number  of  ZZ  carriers  (5000-15000)  followed  by  Belgium,
Portugal,  Serbia  and  Montenegro,  Russia,  Holland,  Norway,
and  Austria,  the  latter  of  which  have  between  1000  and  2000
carriers.
Over  90%  of  individuals  with  clinical  deficiency  carry  the
ZZ  genotype,  while  the  remaining  ones  are  explained  by
other  rarer  variants.17 The  Z  allele  is  most  common  in  north-
ern  Europe,  in  those  of  Scandinavian  descent,  nearly  absent
among  Africans  and  Eastern  populations,  except  where  there
is  miscegenation  with  Europeans,  while  the  S  allele  has
increased  in  the  Iberian  Peninsula.  AATD  is  always  associ-
ated  with  non-Z  alleles  in  Asian  populations.  The  null  allele
occurs  in  a  frequency  of  0.00017.14,17
Few  epidemiological  studies  have  been  carried  out  in
order  to  quantify  the  true  prevalence  of  this  genetic
deficiency  and  information  on  the  Portuguese  population
remains  scarce.  One  study  described  the  geographic  dis-
tribution  of  alleles  across  Portugal  with  S  allele  having
a  decreasing  frequency  from  north  to  south  and  Z  allele
reaching  maximum  frequency  in  the  north  and  minimum
frequency  in  the  centre.18 The  most  relevant  data  pub-
lished  refers  to  a  retrospective  study  that  evaluated  a
sample  of  the  Portuguese  population  tested  for  AATD
over  10  years.19 Data  from  1684  patients  from  almost
every  region  in  Portugal  --  whose  blood/plasma  samples
were  sent  to  an  informal  reference  laboratory  --  were
analysed.  It  was  possible  to  identify  427  MZ,  188  SZ,
and  158  ZZ  subjects.  Different  types  of  rare  deficiency
and  null  alleles  were  also  detected:  59  MMalton or  MPalermo
(p.Phe52del),  28  Q0Ourém (p.Leu353Phefs*24),  21  PLowell
(p.Asp256Val),  17  I  (p.Arg39Cys),  6  MWürzburg (p.Pro369Ser),
6  MHeerlen (p.Pro369Leu),  4  T  (p.Glu264Val),  2  Q0Madrid, 2
Q0Faro (c.-5  +  2dupT),  2  ZAugsburg (p.Glu342Lys),  and  1  Q0Lisbon
(p.Thr68Ile)  variants.  Four  alleles  linked  to  novel  mutations
were  also  identified:  PGaia (p.Glu162Gly),  Q0Oliveira do Douro
(p.Arg281Lysfs*17),  Q0Vila Real (p.Met374Leufs*19),  and  SGaia
(p.Leu118Phe).20,21
DIAGNOSIS OF ALPHA-1 ANTITRYPSIN
DEFICIENCY
In  1963,  Carl-Bertil  Laurell  and  Sten  Eriksson  first  described
AATD  as  a  clinical  entity.22 Since  then,  there  have  been
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mpressive  strides  in  understanding  the  pathobiology  and
linical  course  of  this  inherited  disorder.23 Nevertheless,
any  studies  continue  to  identify  AATD  as  an  under-
ecognized  condition  in  symptomatic  patients.  A  five  to
ight-year  delay  between  the  onset  of  the  first  symptom
usually  dyspnea)  and  the  recognition  of  AATD  has  been
ound  in  studies  performed  over  a  time  span  of  18  years
p  till  2013,  and  there  has  been  no  overall  improvement  in
arly  disease  detection.24--27
LINICAL  MANIFESTATIONS
ATD  by  itself  is  not  a  disease,  but  rather  a  predisposition
o  a  later  development  of  several  disorders.  In  fact,  it  is
elieved  that  low  serum  levels  of  AAT  together  with  other
enetically  determined  characteristics  and  environmental
nfluences  result  in  the  development  of  a  disease  state  that
ay  result  in  premature  death.  The  available  data  on  pen-
tration  (the  percentage  of  AATD  individuals  with  clinical
isease)  is  currently  scant  and  the  spectrum  of  AATD-related
isorders  and  their  ages  of  onset  are  quite  broad.28
In  clinical  practice,  the  risk  of  disease  is  mainly  restricted
o  the  deficient  Z  allele,  accounting  for  approximately  95%
f  AATD  cases.  The  remaining  individuals  at  risk  carry  rare
lleles  including  null  and  dysfunctional  variants.8
Low  levels  of  AAT  represent  a  syndrome  of  clinical  enti-
ies,  some  more  related  to  a  deficiency  condition  while
thers  resulting,  in  contrast,  from  a  negative  effect  of
rotein  overload.  Its  main  clinical  manifestations  primar-
ly  involve  the  lungs,  liver,  and  --  less  frequently  --  the  skin.
ince  patients  with  AATD  are  susceptible  to  developing  all
hese  diseases  throughout  their  lives,  the  disorder  is  consid-
red  a  systemic  disease.29
Individuals  may  be  identified  after  presenting  clinical
onsequences  of  the  deficiency  or  through  family  screening
f  an  index  case.13,30
Currently,  the  understanding  of  the  natural  history  of
ATD  is  still  incomplete.  Within  the  first  three  decades  of
ife,  liver  disease  is  the  major  threat  and  pulmonary  dys-
unction  is  not  common.  Besides  that,  the  natural  history
f  AATD  patients  is  less  clear,  and  survival  estimates  vary
idely  among  series.
.1.  PULMONARY  INVOLVEMENT
n  the  lung,  AATD  predisposes  individuals  to  premature  onset
f  chronic  obstructive  pulmonary  disease  (COPD).  Indeed,
t  is  the  major  and  best  proven  genetic  risk  factor  for
OPD,  with  1-2%  of  all  cases  estimated  to  be  due  to  severe
ATD.28,31
.1.1.  Emphysema
he  premature  onset  of  emphysema  was  the  first  identified
linical  manifestation  of  AATD,  described  in  1963,22 and  it
s  the  most  prevalent  clinical  correlate  of  AATD  and  the
ajor  cause  of  morbidity  and  mortality.32 Emphysema  is
hought  to  primarily  result  from  a  ‘loss  of  function’  defect.8t  corresponds  to  a  protease-antiprotease  imbalance  and
roteolytic  degradation  of  elastin  and  other  extracellular
atrix  components  of  the  respiratory  tract  by  neutrophil
lastase  (NE)  and  other  proteases,  the  activity  of  which  is
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nopposed  and  enhanced  because  of  AATD  in  the  pulmonary
arenchyma  and  airways.  Aside  from  a  quantitative  defi-
iency  in  the  serum,  Z-type  molecules  in  their  monomeric
soforms  are  approximately  fivefold  less  efficient  inhibitors
f  NE  than  normal  native  M-type  AAT.33,34
Compounding  the  lack  of  a  proteolytic  screen,  the  tran-
ition  of  monomeric  Z-AAT  to  polymers  inactivates  its
nti-proteinase  function,  thereby  further  depleting  pro-
ective  levels  of  AAT,  and  also  converts  this  natural
road-spectrum  anti-inflammatory  molecule  into  a  proin-
ammatory  stimulus.  Loop-sheet  polymers  of  misfolded
-types  have  been  shown  to  cause  chemotaxis  and/or  to
ctivate  inflammatory  cells,  hence  supporting  the  hypothe-
is  that  polymers  in  the  lung  (either  circulating  and  trapped
n  the  lung  or  locally  produced  by  alveolar  macrophages
nd  airway  epithelial  cells)  may  contribute  to  tissue
estruction.35 Moreover,  the  accumulation  of  misfolded  AAT
olecules  within  the  ER  lumen  of  mononuclear  phagocytes
nd  neutrophils  leads  to  ER  stress  response  that  may  also
ave  a  role  in  the  pathophysiology  of  lung  disease.36 Indeed,
he  presence  of  polymers  may  explain  the  progression  of
ung  disease  in  Z  homozygotes  after  smoking  cessation
espite  appropriate  intravenous  replacement  with  plasma
AT.37
Individuals  with  genotypes  associated  with  plasma  AAT
evels  below  the  putative  protective  threshold  of  11  M  (cor-
esponding  to  57  mg/dl  by  nephelometry  or  80  mg/dl  by
mmunodiffusion),  most  of  all  homozygous  for  the  deficient
 allele,  are  considered  to  have  severe  AATD.8 Consequently,
hey  are  at  a  markedly  increased  risk  of  early  development
f  panacinar  emphysema,28 particularly  when  exposed  to
igarette  smoke,  environmental  irritants,  or  infections.25
owever,  the  precise  risk  of  developing  emphysema  in  indi-
iduals  with  severe  AATD  is  not  completely  understood.
Although  several  studies  suggest  a  high  risk  of  emphysema
n  ZZ  subjects,  some  never  develop  lung  disease.  Accord-
ngly,  a  post-mortem  series  from  Sweden38 that  included
omputed  tomography  (CT)  imaging  studies39 showed  that
4  to  20%  of  Z  homozygotes  can  be  free  of  emphysema.
Individuals  with  null  alleles  are  at  risk  of  the  most  severe
orm  of  associated  lung  disease,  including  emphysema.
Although  S  homozygotes  are  not  associated  with  a  sig-
ificant  risk  of  emphysema,  SZ  heterozygotes  have  an
ncreased  risk,  particularly  if  associated  with  cigarette
moking.40--43 Moreover,  several  studies  performed  so  far,
ith  differences  in  terms  of  sample  sizing,  have  provided
ontradictory  results  about  an  increased  risk  of  COPD  in
Z  individuals.31,44--47 However,  more  recent  studies  based
n  large  populations  of  patients  and  controls  support  an
ncreased  risk  of  COPD  mainly  influenced  by  exposure  to
igarette  smoke.48
Findings  from  the  National  Heart,  Lung  and  Blood  Insti-
ute  Registry  (NHLBI)  show  that  individuals  with  severe  AATD
isplay  the  same  symptoms  as  patients  with  ordinary,  or
on-AATD,  COPD.  These  symptoms  (in  order  of  decreasing
requency)  include  dyspnea  on  exertion  (84%),  wheezing
ith  upper  respiratory  tract  infections  (URTI)  (76%),  wheez-
ng  without  URTI  (65%),  increased  cough  and  phlegm  (50%)
nd  chronic  cough  (42%).30
Holm  analyzed  cross-sectional  data  collected  via  self-
eport  questionnaires  completed  by  480  individuals  with
on-AATD  COPD  and  578  individuals  with  AATD-associated
g
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OPD.  Individuals  with  AATD-associated  COPD  did  not  report
ore  symptoms  of  depression  (25%  reported  depressive
ymptoms  in  the  clinical  range)  or  anxiety  (36%  reported
linically  relevant  symptoms  of  anxiety)  despite  their
ounger  age;  however,  they  did  report  more  clinically  sig-
ificant  dyspnea  and  greater  impairment  to  health-related
uality  of  life  (HRQoL)  than  other  individuals  with  COPD.49
n  addition,  a  study  which  assessed  the  quality  of  life  of
ortuguese  patients  with  AATD  showed  that  female  patients
ad  worse  HRQoL.  Hospitalizations  and  functional  markers
f  respiratory  disease  progression  negatively  influenced  the
RQoL.50
Considerable  variability  in  the  time  of  symptom  onset  has
een  described,  but  symptoms  rarely  appear  before  25  years
f  age.  Severe  symptoms  are  most  often  seen  in  current  or
ormer  smokers  but  some  smokers  and  many  non-smokers
evelop  no  symptoms  at  all.27 Cigarette  smoking  can  accel-
rate  the  onset  of  dyspnea  by  as  much  as  22  years.  In  three
tudies  the  age  at  onset  of  dyspnea  was  48  to  54  years  in
on-smokers  and  32  to  40  in  smokers.32,51,52
Distinctive  features  of  emphysema  associated  with
evere  AATD  are  early  onset  (i.e.  age  ≤45),  being  present
n  a non-smoker  or  minimal  smoker  who  has  no  occupational
isk  factors  and  basilar-predominant  radiographic  changes.28
ndividuals  with  severe  AATD  experience  a  wide  variation
n  lung  function,  usually  with  an  accelerated  decline.  Esti-
ates  for  the  annual  rate  of  decline  of  forced  expiratory
olume  in  one  second  (FEV1) in  Z  homozygotes  vary  between
3  and  316  ml  and  the  rate  of  decline  is  strongly  affected  by
igarette  smoking.8
The  onset  of  airflow  limitation  typically  occurs  at  a
ounger  age  than  in  usual  for  COPD.  In  a  multicenter  nat-
ral  history  study  of  Alpha1-Antitrypsin  Deficiency  Registry
tudy  Group,  the  mean  FEV1 of  the  1129  participants  was
3  ±  30%  of  that  predicted  and  their  average  age  was  46  ±  11
ears.27 In  non-AATD  COPD  patients,  airflow  limitation  usu-
lly  appears  in  the  sixth  and  seven  decades  of  life.
Several  studies  have  shown  FEV1 values  to  be  a  major
eterminant  of  survival  in  severe  AATD.  Two  year  survival
s  practically  100%  until  FEV1 falls  to  33%  of  that  predicted
nd,  from  this  point  on,  it  decreases  exponentially,  falling
o  50%  when  FEV1 is  15%  of  that  predicted.53
With  COPD,  airflow  obstruction  usually  coexists  with  a
educed  capacity  of  carbon  monoxide  diffusion;  however,
iscordance  is  not  infrequent.  Even  patients  with  severe  air-
ays  obstruction  and  prominent  panacinar  emphysema  on
he  CT  scan  may  have  normal  gas  transfer.54
Variations  in  the  distribution  of  emphysema  may  be  asso-
iated  with  functional  differences  and  therefore  account
or  discordant  physiology.  Basal  distribution  of  emphysema
as  been  associated  with  greater  impairment  of  FEV1 but
ower  impairment  of  gas  exchange  than  the  apical  distribu-
ion.  It  is  possible  that  real  physiological  differences  do  exist
etween  the  upper  and  lower  lung  regions,  and  these  may
e  responsible  for  the  functional  differences  identified.55
The  wide  range  of  clinical  phenotypes  that  are  associated
ith  AATD  could  be  caused  by  interactions  between  genetic
odifiers  and  environmental  factors  other  than  SERPINA1ene  cluster  and  just  smoking.36
The  detrimental  role  of  exposure  to  cigarette  smoke  on
he  clinical  phenotype  of  AATD  has  been  widely  demon-
trated,  with  a significant  gene-by-smoking  interaction.
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Smoke  exposure  is  the  single  greatest  determinant  for  the
progression  of  emphysema  in  AATD  and  a  key  element  in  the
natural  history  of  those  patients.56 There  appears  to  be  a
dose-response  relationship  between  cigarette  consumption
and  change  in  FEV1 over  time.57 Passive  smoking  may  also
be  a  risk  factor  for  respiratory  symptoms,  but  no  relation-
ship  was  found  between  second-hand  smoking  and  decreased
lung  function.58
Active  smoking  --  often  but  not  always  associated  with
lower  FEV1 --  does  not  fully  explain  the  variability,  and
there  are  still  variations  in  the  clinical  course  of  patients
who  have  never  smoked.59 The  natural  history  of  AATD  in
never-smokers  is  altered  at  some  point  in  symptomatic  indi-
viduals,  by  an  unknown  trigger,  worsening  their  condition
and  bringing  them  to  medical  attention.56 Other  risk  fac-
tors  for  airflow  obstruction  may  be  male  gender,  a  parental
history  of  COPD,  and  a  personal  history  of  asthma,  chronic
bronchitis,  or  pneumonia,  among  others.60,61 The  precise
role  of  occupational  inhalation  exposure  in  accelerating  the
loss  of  lung  function  in  AATD  patients  is  not  completely
understood.62,63 There  are  few  data  available  to  indicate
that  long-term  outdoor  air  pollution  (ozone  and  primary  par-
ticles)  can  worsen  the  respiratory  status  and  predict  lung
function  decline  in  individuals  with  the  ZZ  genotype.64,65
In  addition  to  smoking  and  environmental  exposure,  fac-
tors  associated  with  faster  decline  of  lung  function  in  AATD
may  include  male  gender,  age  30  to  44  years,  low  body
mass  index,  lower  serum  AAT  level,  exacerbation  rate,
bronchodilator  reversibility,  and  baseline  severity  functional
capacity.66--68
1.1.2.  COPD  exacerbations
AATD  exacerbations  are  associated  with  greater  inflamma-
tion  and  elastase  activity  than  is  usual  with  COPD,  which
may  explain  why  exacerbations  can  be  more  frequent,
prolonged,  and  severe.69 These  episodes  may  relate  to  phys-
iological  decline  even  in  patients  undergoing  augmentation
therapy.70 In  a  large  one  year  cohort  study  from  United
Kingdom,  neither  the  presence  nor  the  frequency  of  exac-
erbations  showed  a  relationship  to  the  decline  in  FEV1,  but
the  number  of  exacerbations  was  weakly  associated  with  a
decline  in  lung  gas  transfer  for  carbon  monoxide.71
1.1.3.  Spontaneous  secondary  pneumothorax
This  acute  disease  may  be  the  presenting  manifestation  of
AATD72 or  a  complication  of  emphysema.73 To  date,  the
mechanisms  of  spontaneous  pneumothorax  are  still  unclear.
Preliminary  data  of  a  case  control  study  of  39  patients  with
the  diagnosis  of  spontaneous  pneumothorax  confirm  the  clin-
ical  importance  of  AATD  phenotypes  in  those  patients  and
the  need  for  AATD  screening.74
1.1.4.  Asthma
There  is  an  unclear  relationship  between  AATD  and  asthma.
Diagnostic  bias  and  the  overlap  of  COPD  with  asthma  may
be  a  confounding  factor  in  the  evaluation  of  asthma  preva-
lence  among  AATD  subjects.  Although  several  studies  failed
to  prove  an  increased  prevalence  of  AATD  among  asthmatic
patients,75 asthma  has  been  found  to  be  the  most  common
respiratory  complaint  in  patients  with  AATD  prior  to  the  dis-
ease  diagnosis.27
d
b
o
s
antitrypsin  deficiency  5
A  review  published  in  2010  summarizes  information  on
he  relationship  between  severe  AATD,  asthma,  and  COPD.75
urrent  literature  indicates  that  asthma  signs  and  symp-
oms  are  common  and  may  occur  early  in  the  course  of  the
evelopment  of  airflow  obstruction  in  AAT-deficient  patients
ith  or  without  COPD.  Bronchodilator  response  is  a  risk  fac-
or  for  FEV1 decline  and  AATD  itself  predisposes  to  airway
yperresponsiveness  that  is  associated  with  reversible  air-
ow  obstruction.  The  difficulty  in  differentiating  asthma
nd  COPD  in  those  patients  is  particularly  challenging  since
heezing  and  airflow  obstruction  are  common  manifes-
ations  of  both  conditions.  An  increased  awareness  by
linicians  of  the  overlap  between  these  two  conditions  is
undamental  to  ensure  appropriate  therapeutic  strategies  in
rder  to  prevent  an  accelerated  decline  of  lung  function.75
.1.5.  Bronchiectasis
ronchiectasis  has  also  been  associated  with  severe  AATD,
ut  the  relationship  between  these  conditions  remains
nclear  and  the  estimated  prevalence  varies  widely  across
ifferent  reports.41,76,77
The  Portuguese  recommendations  are  for  the  aetiological
iagnosis  of  bronchiectasis;  given  the  high  frequency  of  defi-
ient  alleles  in  the  Portuguese  population  and  the  benefit  of
arly  AATD  detection,  testing  for  AATD  should  be  undertaken
or  all  subjects  with  bronchiectasis.78
XTRAPULMONARY DISEASE
n  addition  to  extrapulmonary  disease,  liver  and  skin  dis-
rders  may  also  occur  in  AATD.  Clinical  evidence  of  an
ssociation  with  other  diseases  such  as  bowel  disease,
lomerulonephritis,  rheumatoid  arthritis,  fibromyalgia,  vas-
ular  abnormalities  (fibromuscular  dysplasia  of  the  arteries,
bdominal  and  brain  aneurysms,  and  arterial  dissection),
soriasis,  chronic  urticaria,  pancreatitis,  neoplasia,  and
ultiple  sclerosis,  is  rare  and  further  research  studies  are
equired  prior  to  reaching  any  conclusions.79
iver  Disease
iver  disease  does  not  occur  frequently.  AATD  is  only  diag-
osed  through  finding  of  liver  disease  in  3%  of  AATD  cases.80
nlike  pulmonary  disease,  AATD-related  hepatopathy  is
ot  caused  by  functional  loss  or  low  protein  serum  lev-
ls  but  rather  by  the  accumulation  of  AAT  polymers  in
epatocytes.81 In  this  context,  liver  disease  is  the  result  of
 disrupted  balance  between  the  accumulation  of  AAT  poly-
ers  and  the  capacity  of  cellular  mechanism  to  degrade
hose  protein  aggregates.81,82 Hence,  those  AATD  variants
inked  to  polymerization  in  the  liver,  such  as  SIiyama,  MDuarte,
Malton, and  particularly  Z  allele,  may  all  show  signs  of  hep-
topathy.  Liver  disease  has  never  been  reported  in  Null
Q0Q0)  patients.  Unlike  pulmonary  disease,  which  is  typ-
cally  a disorder  of  adulthood,  liver  disease  may  occur
hroughout  a  patient’s  life;  it  is  a  frequent  cause  of  dis-
ase  in  non-smokers.  The  prevalence  of  post-mortem  liver
isease  in  non-smokers  is  28%.  Approximately  10-15%  of  new-
orns  with  severe  AATD  are  at  risk  of  developing  some  form
f  liver  disease.  Similarly,  about  10  to  15%  of  adults  show
ome  evidence  of  liver  disease,  and  although  it  may  occur
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t  any  given  age,  it  occurs  more  frequently  later  in  life.80
holestatic  jaundice  and  hepatitis  (neonatal  hepatitis  syn-
rome)  can  be  observed  in  some  new-borns  with  AATD,  while
ater  during  childhood  AATD  patients  may  experience  an
nexplained  increase  in  aminotransferases,  hepatomegaly,
r  on  rare  occasions,  cirrhosis  and  liver  failure.  In  some
ases,  the  only  signs  of  liver  disease  in  young  children  may
e  anorexia  and  a  growth  delay.83 On  the  other  hand,  adults
ay  show  asymptomatic  changes  in  transaminases,  clini-
al  signs  of  cirrhosis,  and  hepatocellular  carcinoma.  Clinical
anifestations  in  patients  with  chronic  liver  disease  due  to
ATD  may  not  be  differentiated  from  those  of  any  other
tiology.
The  development  of  liver  disease  and  its  evolution
owards  cirrhosis  is  the  most  common  clinical  sign  after
ulmonary  disease.  It  is  estimated  to  occur  in  2-43%  of  ZZ
atients.  It  may  be  a  frequent  cause  of  death  in  non-smokers
ith  the  ZZ  phenotype.84 According  to  a  Swedish  study,  out
f  a  population  of  200  000  newborns,  22/120  Z  individuals
18%)  showed  signs  of  some  liver  dysfunction,  which  included
bstructive  jaundice  (12%)  and  discrete  lab  changes  (7%).85
he  risk  of  cirrhosis  in  these  cases  was  approximately  50%,
pproximately  25%  died  during  the  first  decade,  and  2%
eveloped  cirrhosis  later  on  in  their  childhood.86 The  follow-
p  of  127  ZZ  newborns  until  their  30s  showed  that  3-7%  had
igh  transaminase  levels,  but  none  of  them  showed  any  clin-
cal  symptoms  of  liver  disease.87 In  a  second  study  where  246
Z  patients  were  followed  over  an  11-year  period,  Larsson
bserved  liver  disease  in  12%  of  the  cases  (cirrhosis  in  11.8%,
eonatal  hepatitis  in  0.4%,  and  hepatoma  in  3.3%).32 ZZ  indi-
iduals  who  develop  cirrhosis  are  at  an  increased  risk  of
eveloping  hepatocellular  carcinoma,88 especially  middle-
ged  or  older  men,  although  there  have  been  some  rare
ases  described  in  children.89 However,  this  risk  has  been
ifficult  to  quantify  and  may  vary  across  studies.88
The  risk  of  heterozygous  patients  developing  liver  disease
s  not  well  established.  Many  studies  have  shown  that  there
s  a  greater  prevalence  of  the  MZ  genotype  among  patients
ith  cirrhosis  than  in  control  populations  with  non-cirrhosis
iver  disease  or  cryptogenic  cirrhosis.90--94 However,  a  more
ecent  study  has  not  shown  any  association  between  the  MZ
enotype  and  liver  disease.95 The  risk  of  individuals  with  one
 allele  developing  hepatocellular  carcinoma  is  also  not  as
ell  defined  as  for  homozygous  patients.  Heterozygosity  for
he  Z  allele  may  increase  the  risk  or  change  it  in  patients
ith  other  liver  diseases,  such  as  chronic  hepatitis  C.96
anniculitis
anniculitis  was  described  for  the  very  first  time  by  Warter  in
972  and  it  has  been  associated  with  AATD  in  approximately
0  reported  cases.  Panniculitis  is  very  rare  with  an  estimated
revalence  of  1  per  1000  AATD  cases,30 and  with  an  aver-
ge  age  of  appearance  of  40  years.  As  with  emphysema,
anniculitis  is  thought  to  occur  due  to  a  lack  of  protease
nhibitory  activity  in  the  skin.  It  is  characterized  by  pain
nd  one  or  more  nodules  showing  exuding  liquid  and  red-
ess,  and  painful  and  warm  cutaneous  plaques,  which  may
uffer  necrosis  and  be  recurrent.  Although  it  occurs  more
ften  on  the  thighs  and  buttocks,  in  one  third  of  cases  it  will
ccur  in  places  of  trauma.  There  are  rare  situations  where  it
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ay  be  accompanied  by  polyserositis.  It  may  occur  in  several
isease  genotypes,  including  ZZ,  SZ,  SS,  and  MS.97 Diagno-
is  requires  deep  excisional  biopsy,  which  shows  areas  of
at  necrosis  interspersed  among  normal  areas.  A  differen-
ial  diagnosis  with  other  causes  of  panniculitis  is  difficult
nd  that  is  why  AAT  levels  should  be  measured  in  every  case
f  necrotising  panniculitis.
asculitis
n  association  between  antiproteinase  3  (PR3)  antibody  vas-
ulitis  (c-ANCA  positive)  and  AATD  was  first  reported  in
993.98,99 Since  then,  several  series  have  established  a  cor-
elation  between  AATD  phenotypes  and  anti-PR3  vasculitis.
owever,  there  is  a  low  incidence  of  antiproteinase  3  anti-
odies  in  patients  with  AATD  and  its  presence  may  not  be
elated  to  the  development  of  systemic  vasculitis.100 Taking
nto  account  this  association,  AATD  testing  must  be  carried
ut  in  adults  with  c-ANCA  positive  vasculitis.28
ABORATORY TESTS
iagnostic  tests  to  confirm  the  presence  of  AATD  are  divided
nto  quantitative  and  qualitative  tests.  There  are  four  types
f  tests:
-  Serum  AAT  Test,  quantitative  test  for  determining  the
amount  of  protein  in  the  blood;
-  AAT  Phenotyping,  qualitative  test  that  assesses  the  pro-
tein  variants  in  the  blood.  This  technique  is  capable  of
detecting  normal  alleles  (M)  and  deficiency  alleles  (S,  I,  Z,
and  others)  but  it  will  not  detect  null  alleles  (i.e.  Q0Ourém);
- AAT  Genotyping,
 Searching  for  S  and  Z  mutations,  qualitative  test  that
assesses  the  presence  or  absence  of  the  most  common
mutations  in  deficiency  -  S  and  Z  alleles.
 SERPINA1  gene  sequencing,  qualitative  test  that  is  con-
sidered  the  reference  method  for  identifying  specific
mutations  associated  with  AAT  rare  alleles,  whether  they
are  deficient  or  null  (I,  MMalton, PLowell,  Q0Ourém,  etc.).
erum  AAT  TEST
he  concentrations  of  AAT  serum  levels  may  be  measured
sing  several  different  methods:  immunoelectrophoresis,
adial  immunodiffusion  and  nephelometry,  and  normal  val-
es  will  vary  depending  on  the  method  used101 (Table  1).
owadays,  the  most  commonly  used  method  is  nephelom-
try.  Radial  immunodiffusion  and  nephelometry  tend  to
verestimate  the  concentration  of  AAT  when  compared  to
he  purified  standard  test  developed  by  the  US  National  Insti-
ute  of  Health.  In  order  to  differentiate  the  values  obtained
sing  the  non-purified  standard  test  from  those  obtained
sing  the  purified  standard  test,  the  former  are  expressed  in
g/dl  while  the  latter  are  in  M.  Both  units  are  frequentlysed  and  are  interchangeable  in  many  European  countries,
hatever  the  test  used.  In  order  to  convert  mg/dl  (neph-
lometry)  to  M,  one  must  multiply  the  concentration  in
g/dl  by  0.1923.79
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Table  1  Normal  and  protective  serum  levels  of  AAT  in  the  several  testing  methods.
Method  Normal  values  Protective  threshold
Purified  standard  test  20-53  M  11  M
Nephelometry  83-120  a  200-220  mg/dl  57  mg/dl
Radial immunodiffusion  150-200  a  350
Table  2  Main  AAT  genotypes  and  related  serum  levels.
Genotype AAT  serum  level
mg/dl* M**
MM  103-200  20-39
MS 100-180  19-35
SS 70-105  14-20
MZ 66-120  13-23
SZ 45-80  9-15
ZZ 10-40  2-8
Q0Q0 0  0
*
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Only  when  genotyping  includes  the  amplification  of  SER-nephelometry
** purified standard test)
The  reference  values  for  each  method  are  shown  in
Table  1.  In  order  to  make  it  easier  to  interpret  results,  each
laboratory  must  previously  determine  the  normal  values  of
AAT  in  the  serum  samples  of  normal  individuals.79
Bearing  in  mind  that  different  alleles  determine  a  differ-
ent  percentage  of  protein  production,  there  are  expected
serum  levels  for  each  phenotype79 (Table  2).
AAT  behaves  like  an  acute  phase  protein,  which  is  why
its  serum  levels  may  be  falsely  augmented  during  inflamma-
tory  and  infectious  processes.  Therefore,  AAT  tests  must  be
carried  out  preferably  outside  these  episodes.  Higher  AAT
values  can  be  also  found  during  pregnancy  and  after  taking
oral  contraceptives.  In  these  cases,  normal  serum  levels  may
be  detected  in  patients  with  moderate  deficiency.  Serum
levels  are  lower  in  children  than  in  adults.79
DETERMINING  THE  NEUTROPHIL  ELASTASE
INHIBITORY  CAPACITY
In  rare  circumstances,  another  test  may  be  used  to  assess
if  a  patient  with  normal  circulating  levels  has  an  AATD.
The  inhibition  of  NE  by  AAT  is  directly  related  to  its  serum
concentration  in  such  a  way  that  a  greater  amount  of  AAT  cir-
culating  will  have  greater  inhibitory  effect.  However,  some
patients  may  present  normal  or  high  AAT  levels  and  little
anti-elastase  activity  due  to  the  fact  that  not  every  pro-
tein  is  active  (80%  be  oxidised,  destroyed,  or  not  capable  of
linking  to  neutrophils).
Measuring  the  capacity  to  inhibit  elastase  from  neu-
trophils  is  especially  indicated  in  the  following  cases:  1)
studying  patients  with  COPD  where  AATD  is  suspected
although  with  a  normal  AAT  serum  level;  2)  when  determin-
ing  if  during  an  exacerbation  of  COPD  the  increase  in  AAT  is
proportional  to  anti-elastase  activity;  3)  when  assessing  the
implication  of  AAT  deficiency  in  the  severity  of  pulmonary
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isease,  since  quite  often  AAT  serum  concentration  is  not
elated  to  clinical  progress.79
ETERMINING  PHENOTYPE  AND  GENOTYPE
ualitative  tests  detect  the  different  mutations  of  the
ERPINA1  gene. While  phenotyping  is  carried  out  using
soelectric  focusing  (IEF)  techniques  that  allow  for  the  iden-
ification  of  several  protein  variants  in  the  blood  (S,  Z,
,  and  others),  genotyping  usually  covers  different  varia-
ions  to  the  polymerase  chain  reaction  (PCR)  method,  which
nables  the  analysis  of  different  mutations  in  more  or  less
xtensive  regions  of  the  SERPINA1  gene.
.1.6.  Phenotyping
everal  protein  variants  present  in  the  blood,  corresponding
o  different  alleles  of  the  SERPINA1  gene,  may  be  identified
hrough  isoelectric  focusing.
Although  phenotyping  permits  the  characterisation  of
pproximately  30  AATD  variants,  this  method  alone  will  not
e  sufficient  for  a  complete  diagnosis  in  the  case  of  null
ariants  with  very  low  (MHeerlen) or  virtually  non-detectable
Q0Ourém) protein  serum  levels.  Phenotyping  may  also  lead  to
 partial  diagnosis  in  the  case  of  M-like  (MMalton and  MWurzburg)
ariants  which,  in  addition  to  presenting  reduced  concen-
rations  of  protein,  show  a  very  similar  migration  pattern  to
 protein.
.1.7.  Genotyping
ifferent  methods  based  on  the  PCR  technique  have  been
sed  for  genotyping  the  mutations  that  define  the  S
rs17580,  p.Glu264Val  or  c.863A>  T)  and  Z  (rs28929474,
.Glu342Lys  or  c.1096G>  A)  alleles,  which  use  either  primer
ligonucleotides  or  specific  fluorescent  probes  (in  the  case
f  real  time  PCR  detection),  detecting  exclusively  the
utated  (S  and  Z)  or  non-mutated  (non-S  and  non-Z)  posi-
ion  in  the  DNA  sequence.102 In  spite  of  these  methods
eing  technically  simpler  and  more  likely  to  be  applied  to
 broader  genetic  screening  of  AATD,  they  do  not  enable  us
o  detect  the  presence  of  other  mutations  which  occur  in
ortugal.21 If  while  using  these  techniques  S and/or  Z  alle-
es  are  not  detected,  patients  will  be  frequently  catalogued
s  carrying  the  M  allele  (homozygosity  or  heterozygosity)
ince  in  the  case  of  the  Portuguese  population  the  most  fre-
uent  alleles  are  M  (80-86%)  followed  by  S  (12-18%)  and  Z
1-2.5%).103,104 This  field  is  rapidly  advancing  and  soon  there
ill  be  diagnostic  kits  capable  of  detecting  a  greater  number
f  mutations  of  the  SERPINA1  gene.INA1  coding  regions  (exons  II  to  V)  and  DNA  sequencing  does
t  become  possible  to  assess  in  a  systematic  manner  the  AATD
enetic  variation.  It  may  be  complemented  by  an  analysis
8  A.P.  Lopes  et  al.
Clinical suspiction of AATD
Measure AAT serum levels
Phenotyping or genotyping
(by allelle specific methods)
Intermidiate deficiency
57-110mg/dL
Others
Genotyping
SZ,MZ,
MS,SS
MMZZ
(SZ)
Probably without AATD
(probable MM phenotype)
>110mg/dL
Others
(null-null,znull,
z-rare, null-rare)
Severe deficiency
< 57mg/dL
<110mg/dL
diagn
o
i
n
t
f
r
s
t
r
t
s
a
d
o
s
t
-
l
t
A
t
r
b
t
c
4
c
e
b
p
s
d
v
h
t
s
c
i
s
i
m
a
p
w
t
a
s
s
H
o
t
n
a
1
G
d
o
d
a
o
e
i
2
h
a
a
a
i
i
M
D
T
s
o
test,  often  by  nephelometry.28Figure  1  AATD  
f  the  exon-intron  regions  and  the  promoter  (exons  Ia  to  Ic)
n  order  to  rule  out  eventual  mutations  that  may  affect  the
ormal  processing  of  mRNA  (Q0Oporto and  Q0Faro).104 Although
his  form  of  genotyping  may  represent  an  excellent  method
or  diagnosing  AATD,  currently  its  costs  and  technological
equirements,  particularly  in  less  specialised  laboratories,
till  prohibit  its  use  as  a  screening  tool.  Hence,  this  excep-
ional  method  is  only  used  to  confirm  diagnosis  in  the  case  of
are  AATD  alleles  that  have  been  identified  through  isoelec-
ric  focusing  (phenotyping),  in  particular  situations  where
erum  levels  diverge  from  phenotype  and/or  genotype  (S
nd  Z  mutation  search),  when  results  are  inconclusive  or
o  not  agree  with  the  clinical  manifestations,  or  whenever
ther  rare  or  null  variants  are  suspected.79
Considering  the  complexity  of  the  AATD  genetic  diagno-
is,  partly  due  to  the  large  number  of  rare  variants,104 and
he  specificities  and  limitations  of  each  different  technique
- genotyping  and  phenotyping  --,  the  different  reference
aboratories  in  Europe  have  established  different  diagnos-
ic  algorithms,  which  often  combine  the  measurement  of
AT  serum  levels,  the  search  for  S  and  Z  mutations,  isoelec-
ric  focusing,  and  the  SERPINA1  gene  sequencing  in  order  to
educe  the  number  of  false  negatives  and  positives.105
Phenotype  and/or  genotype  may  be  determined  in  a  total
lood  sample  preferably  resorting  to  the  ethylenediamine
etraacetic  acid  (EDTA)  anticoagulant,  which  should  be  pro-
essed  into  two  segments  within  an  approximate  timespan  of
8  h:  plasma  or  serum  (for  isoelectric  focusing)  and  mononu-
lear  blood  cells  or  total  remaining  blood  (for  genomic  DNA
xtraction).  In  any  case,  the  different  blood  fractions  may
e  stored  at  -4 ◦F  (-20 ◦C).79 The  timely  execution  of  this
rocedure  is  crucial  in  order  to  identify  deficient  variants,
uch  as  the  Z  allele,  given  its  lability  and  consequent  risk  of
eterioration.
Recently,  as  an  alternative  to  collecting  samples  by
enipuncture,  rapid  genetic  screening  methods  (kits)
ave  been  provided,  which  enable  a  quick  assessment  of
he  presence  of  S  and  Z  alleles  in  blood  (Alphakit®)  or
aliva  samples.  However,  these  tests  still  require  result
onfirmation  using  more  conventional  methods,  particularly
f  one  of  these  alleles  is  detected,  or  if  AATD  is  strongly
uspected.  Currently,  there  are  also  AATD  genetic  screen-
ng  programmes,  which  favour  sample  collections  using
r
s
(gene sequencing in reference laboratory)
ostic  algorithm.
inimally  invasive  methods  by  means  of  finger  puncture
nd  collection  of  a  small  amount  of  blood  on  dry  filter
aper  (DBS:  dried  blood  spots),  which  may  be  sent  by  post
ithout  any  extra  care.  Several  studies  have  shown  that
esting  and  searching  for  S  and  Z  mutations  by  means  of
 dried  blood  drop  sample  is  feasible  and  it  is  particularly
uitable  for  the  purpose  of  screening  in  a  larger  population,
ince  it  is  a  simpler  and  cheaper  sampling  method.105--109
owever,  due  to  the  lower  quantity  and  quality  of  the
btained  sample,  in  some  cases  --  particularly  regarding
he  SERPINA1  gene  sequencing  and  phenotyping  --  it  may  be
ecessary  or  even  desirable  to  confirm  results  by  means  of
 total  blood  sample  collected  by  venipuncture.28,105
.1.8.  AATD  Genotypes
enotypes  that  increase  the  risk  of  developing  pulmonary
isease  are  associated  with  serum  values  lower  than  11  M
r  57  mg/dl  (protective  threshold)  which  may  result  from
ifferent  combinations  of  deficient  (Z,  MMalton or  other  rare
lleles)  and  null  (Q0Ourém or  others)  alleles  in  homozygosity
r  heterozygosity  such  as  ZZ,  SQ0,  ZQ0,  Q0Q0  or  with  lev-
ls  of  serum  similar  to  these  (Table  2).  Intermediate  AATD
s  characterised  by  serum  concentrations  between  11  and
0  M  and  associated  to  several  genotype  combinations  in
omozygosity  or  heterozygosity,  such  as  SS,  SZ,  MZ,  MS,  SQ0,
nd  MQ0,  among  others79,101 (Table  2).
On  the  other  hand,  genotypes  that  have  been  described
s  being  associated  with  a  greater  risk  of  liver  disease
re  those  associated  with  homozygosity  or  heterozygos-
ty  for  alleles  with  proven  susceptibility  to  form  polymers
n  hepatocytes  (Z,  S,  MMalton, MPalermo,  MNichinan,  SIiyama and
Wurzburg).2,21
IAGNOSTIC ALGORITHM
he  AATD  diagnostic  algorithm  (Fig.  1)  begins  with  a  clinical
uspicion  of  AATD  (Table  3).  In  this  case,  the  quantification
f  AAT  serum  levels  is  recommended  by  doing  a  quantitativeThe  consensus  document  from  the  American  Tho-
acic  Society  and  European  Respiratory  Society  (ATS/ERS)28
uggests  the  combination  of  the  quantitative  test  and
Portuguese  consensus  document  for  the  management  of  alpha-1-
Table  3  Clinical  cases  where  an  AATD  screening  is
recommended.
Clinical  Suspicion  of  AATD:  Candidates  for  AAT  values  to
be determined
All COPD  patients
Early  pulmonary  emphysema  (patients  younger  than  45)
Emphysema  when  not  exposed  to  known  risk  factors
(smoking  and  occupational  factors)
Panlobular  emphysema  that  is  predominantly  basal
Asthma with  spirometry  that  does  not  normalize  in  spite
of adequate  therapy
Adults  with  bronchiectasis
Teenagers  with  a  persistent  obstruction  in  lung  function
tests
A clinical  history  of  dyspnea  and  chronic  coughing  in
several  members  of  the  family
Hepatopathy  of  unknown  cause
Decrease  in  the  peak  of  the  alpha-1  protein  in  the
proteinogram
Panniculitis  or  vasculitis  of  unknown  cause
Relatives  of  AATD  patients  (brothers  and  sisters,
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be  sent  to  a  reference  laboratory  in  order  to  make  a
correct  diagnosis.offspring,  parents,  others)
phenotyping  as  gold  standard  for  the  diagnosis  of  AAT  defi-
cient  states.  In  a  recent  document  updating  the  Spanish
guidelines,110 this  algorithm  continues  to  be  recommended
with  high  quality  scientific  evidence,  since  it  enables  us  to
clarify  most  AATD  cases.  However,  some  authors  defend  the
association  of  a  quantitative  test  with  genotyping  as  the
best  method  for  diagnosis.105,111,112 Whatever  the  test  used,
there  should  be  a  concordance  between  the  identified  phe-
notype/genotype  and  the  measured  serum  level  (Table  2).
According  to  ATS/ERS28 recommendations,  individuals
with  a  AAT  serum  level  below  the  normal  value,  or  between
90-140  mg/dl  through  nephelometry,  which  are  considered
as  borderline  values,  should  undertake  a  qualitative  test
that  includes  phenotyping  and/or  genotyping,  since  these
values  may  correspond  to  a  phenotype  with  intermediate
deficiency  (SZ,  SS,  MZ)  and  there  may  be  relatives  with  a
severe  deficiency.  According  to  Ferrarotti,113 the  following
cut-off  points  were  proposed:  1)  If  the  purpose  is  to  iden-
tify  genotypes  with  an  increased  risk  of  emphysema,  then  a
100  mg/dL  cut-off  point  is  sufficient  (95.8%  sensitivity,  94.8%
specificity);  2)  If  the  purpose  is  to  detect  all  patients  carry-
ing  Z  and  S  alleles,  then  a  110  mg/dL  cut-off  point  should  be
used  (73.4%  sensitivity,  88.5%  specificity);  3)  Other  studies
have  used  a  113  mg/dL  cut-off  point,  since  there  are  no  Z
alleles  or  SS  individuals  above  this  value  (100%  sensitivity,
78%  specificity  for  AATD  and  79%  sensitivity  and  83%  speci-
ficity  for  detecting  Z  and  S  alleles).  There  is  a  high  number
of  false  positives  above  these  values.114
Based  on  this,  we  recommend  a  qualitative  whenever  the
serum  level  is  below  110  mg/dl.
The  genetic  diagnosis  of  AATD  should  be  supported
by  reduced  serum  levels  (<110  mg/dl)  and  a  compatible
phenotype  or  genotype  that  is  recognised  as  being  related
to  the  disease.  Whenever  the  serum  levels,  phenotype,
or  genotype  do  not  agree  with  each  other  or  with  clinical
manifestations,  then  a  rare,  deficient,  or  null  variant  shouldantitrypsin  deficiency  9
e  considered,  and  it  should  be  investigated  by  a  reference
aboratory  in  order  to  clarify  the  situation.
CREENING
n  light  of  the  misdiagnosis  and  delay  in  the  diagnosis  of
ATD,  in  Portugal  and  in  the  rest  of  the  world,  it  is  mandatory
o  screen  risk  groups  if  we  wish  to  change  this  panorama.
arly  diagnosis  and  proper  follow-up  should  lead  to  pre-
entive  attitudes  and  lifestyle  changes  that  will  certainly
hange  the  progress  of  this  disease  --  smoking,  occupational
xposure,  and  infections  --, early  treatment  of  symptoms
nd  exacerbations  and  administration  of  replacement  ther-
py  in  the  early  stages  of  the  disease  in  order  to  improve
ife  quality  and  expectancy  of  these  patients.  Therefore,  it
s  imperative  to  identify  the  disease  as  soon  as  possible.
However,  identifying  individuals  with  AATD  may  also  carry
ome  risks,  such  as  genetic  discrimination,  a  high  psycholog-
cal  burden,  and  may  have  employment  implications.  Hence,
efore  doing  the  screening,  doctors  should  weigh  the  pros
nd  cons  of  diagnosis  and  discuss  them  with  the  patient.28
Screening  is  recommended  for  patients  who  are  clinically
uspected  for  AATD  (Table  3).  In  the  case  of  screening  rela-
ives  of  the  index  case,  it  has  not  yet  been  established  how
ide  this  screening  should  be,  although  some  advise  that
rst  degree  relatives  should  be  tested.115
The  screening  method  should  be  similar  to  that  used  in
he  diagnosis  and  follow  the  same  algorithm.
The  implementation  of  national  screening  programmes
s  leading  to  an  increase  in  the  number  of  detected  cases.
ountries  where  screening  programmes  have  already  been
mplemented116--119 show  different  detection  rates.  Many  of
hese  programmes  are  carried  out  as  an  initiative  of  the
ATD  National  Registries.  When  designing  a  screening  pro-
ramme  for  detecting  AATD,  one  must  consider  the  sample
rocess  protocol  as  well  as  criteria  for  including  candi-
ates,  since  both  factors  will  have  a  decisive  impact  on
he  programme  results  and  cost.120 We  suggest  screening
rogrammes  using  accurate  and  simple  methods  with  dried
lood  drop  samples  where  AAT  is  tested  and  phenotyping
nd/or  genotyping  is  carried  out  using  fast  methods  which
re  cost-effective.
Key  Points: Diagnosis
-  AATD  diagnosis  begins  with  a  clinical  suspicion  that
should  be  confirmed  by  AAT  serum  levels  and  pheno-
typing  and/or  genotyping.
-  AAT  serum  levels  <  110mg/dl  (nephelometry)  should
prompt  to  phenotyping  and/or  genotyping
-  There  should  be  agreement  between  serum  levels
and  the  phenotype/genotype,  otherwise  we  could  be
in  the  presence  of  a  rare  allele.
-  If  there  is  suspicion  of  a  rare  allele,  samples  should
10  A.P.  Lopes  et  al.
Table  4  Additional  exams  in  the  early  stages  of  confirmed  AATD.
Pulmonary  Assessment  Liver  Assessment
Spirometry  Liver  function  tests
Pulmonary  volumes  Abdominal  ultrasound  (or  Fibroscan TM)
DLCO
Arterial blood  gas  analysis
Chest  X-ray
Chest  CT  (with  emphysema  quantification,  if  available)
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Six-minute  walk  test
NITIAL ASSESSMENT OF A PATIENT SUFFERING
ROM ALPHA-1 ANTITRYPSIN DEFICIENCY
he  initial  assessment  of  a  patient  with  AATD  should  begin
ith  a  medical  history  and  physical  exam  with  special  focus
n  pulmonary  disease  as  well  as  in  the  other  clinical  mani-
estations  of  the  disease,  such  as  liver  and  skin  disease.
In  addition  to  the  AAT  test  and  phenotyping/genotyping,
hich  were  carried  out  during  screening  and  diagnosis,  addi-
ional  exams  should  be  undertaken  in  the  early  stages  of  a
atient  with  confirmed  AATD  (Table  4).
ULMONARY ASSESSMENT
ung  Function  Tests
he  initial  assessment  of  a  patient  with  AATD  should  include:
pirometry  --  before  and  after  a  bronchodilator  --, pulmonary
olumes  --  measured  either  through  plethysmography  or  the
elium  dilution  technique  or  nitrogen-washout  --, carbon
onoxide  diffusion  capacity,  arterial  blood  gas  analysis,  and
-minute  walk  test.28 Other  respiratory  function  exams  may
e  carried  out  in  selected  cases.
Spirometry  is  the  most  suitable  exam  for  the  diagnosis  of
OPD  and  for  assessing  its  progression.  There  is  usually  an
bstructive  pattern  (FEV1/FVC<  0,7)  with  a  decrease  in  FEV1
nd  normal  or  decreased  forced  vital  capacity  (FVC).  The
ow-volume  curve  shows  a  notch  in  the  expiratory  portion
eading  to  a  high  decrease  in  flow  with  progressively  lower
olumes.  Most  patients  do  not  have  a  positive  bronchodilator
esponse,28 although  there  may  be  moderate  reversibility  in
p  to  49%  cases  (≥12%  and  ≥200  ml  in  FEV1).121,122 There  may
lso  be  reversibility  in  12.5%  of  patients  with  normal  FEV1,
uggesting  that  hyperreactivity  may  be  an  early  character-
stic  of  this  disease.121
In  the  later  stages  of  the  disease,  loss  in  the  lung  elas-
ic  recoil  will  result  in  an  increased  pulmonary  compliance
ith  hyperinflation,  which  translates  into  a  decrease  in
VC  and  an  increase  in  total  lung  capacity  (TLC)  and  in
esidual  volume  (RV).  Hence,  adding  measurement  of  the
ulmonary  volumes  to  spirometry  will  allow  for  better  and
ore  complete  patient  assessment.  Due  to  the  effect  of  air
ntrapment,  the  pulmonary  volumes  measured  by  plethys-
ography  are  usually  greater  than  those  measured  usingelium-dilution  based  techniques28;  therefore,  they  should
e  measured  preferably  using  the  first  method.
Measuring  carbon  monoxide  diffusing  capacity  (DLCO)
ill  assess  gas  exchange  through  the  alveolar-arterial
T
fi
w
i
embrane,  which  is  usually  reduced.  Although  these  two
spects  belong  to  the  same  process  (emphysema),  FEV1 and
LCO  do  not  always  correlate.28 Arterial  blood  gas  analysis
lso  enables  us  to  assess  gas  exchange.  There  may  not  be
ny  changes  in  the  early  stages,  but  as  the  disease  pro-
resses,  hypoxemia  will  appear  with  exercise  and  then  while
esting,  and  will  later  on  be  associated  with  hypercapnia.
In  the  later  stages  of  the  disease  the  effect  of  emphysema
n  the  muscular  activity  of  the  chest  and  diaphragm  may
e  assessed  by  measuring  inspiratory  and  expiratory  muscle
ressures.
Respiratory  function  in  exercise  may  be  assessed  by
eans  of  exercise  tests  such  as  the  six-minute  walk  test  or
he  cardio-pulmonary  exercise  test.  In  later  stages  of  the  dis-
ase,  cardio-pulmonary  exercise  test  may  show  a  decrease
n  the  PaO2  and  an  increase  in  the  alveolar-arterial  dif-
erence.  Patients  suffering  from  AATD  may  have  increased
espiratory  rates  while  resting  and  their  minute  ventilation
ay  exceed  80%  of  predicted  maximum  voluntary  ventilation
uring  mild  exercise,  which  is  an  indication  that  ventilation
ay  limit  higher  levels  of  exercise.28 The  6-minute  walk  test
ssesses  not  only  the  exercise  functional  capacity,  but  it  is
lso  important  to  estimate  disease  prognosis  by  calculating
he  BODE  index.
maging  Exams
hest  X-ray  should  be  carried  out  during  the  initial  assess-
ent  of  all  patients.  However,  high-resolution  CT  of  the
hest  in  order  to  assess  the  bronchopulmonary  morphology
r  chest  CT  with  thicker  sections  for  densitometry  are  the
est  exams  for  detecting  and  quantifying  the  presence  of
mphysema.
hest  X-ray
hest  X-ray  is  the  norm  in  the  early  stages  of  the  disease.
s  the  disease  progresses  the  typical  signs  of  hyperinflation,
uch  as  an  increase  in  the  anteroposterior  and  lateral  diam-
ter  of  the  chest,  higher  transparency  of  the  pulmonary
elds,  a  decrease  in  the  vascular  markings,  horizontaliza-
ion  of  the  ribs,  an  increase  in  the  intercostal  spaces,  low
nd  rectified  hemidiaphragm,  and  vertical  heart,  appear.
hese  changes  are  usually  more  prominent  in  the  lower  lung
elds.28 Bullous  changes  do  not  occur  very  often  in  AATD  and
hen  they  do  occur  (35%)  their  most  likely  location  is  in  the
nferior  lobes.123
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Portuguese  consensus  document  for  the  management  of  alp
Chest  CT
Chest  CT  is  the  best  exam  in  vivo  for  characterising  the
severity  and  morphology  of  pulmonary  emphysema,124 bet-
ter  than  a  chest  X-ray  or  respiratory  function  tests.28 It  has
a  positive  correlation  with  pathological  findings,  and  that  is
why  it  has  been  suggested  as  the  best  method  for  monitor-
ing  emphysema  progression.101 The  possibility  of  measuring
pulmonary  density  enables  quantification  of  the  extent  of
emphysema  which  can  be  used  to  monitor  disease  progres-
sion.
In  AATD,  the  emphysema  is  usually  of  the  panlobular
type28 and  in  2/3  patients  it  particularly  affects  the  basal
regions,  in  contrast  to  the  centrilobular  emphysema  pre-
vailing  in  the  upper  lobes  which  is  typical  of  emphysema
caused  by  smoking.  However,  in  up  to  36%  of  the  cases  the
emphysema  may  be  diffuse  or  eventually  apical.55
In  CT,  the  emphysema  areas  are  characterised  by  a  par-
ticularly  low  attenuation,  in  contrast  to  the  surrounding
parenchyma  in  density  values  in  Hounsfield  units  (HU).  Chest
CT  provides  for  calculation  of  densitometry  parameters,
making  it  possible  to  assess  the  extent  of  the  emphysema.
There  are  several  methods  for  calculating  these  densito-
metric  parameters:  the  ‘‘density  mask’’,  the  ‘‘percentile
method’’,  and  the  ‘‘average  parenchyma  density’’.  The
density  mask  method  uses  a  cut-off  value  (usually  -910HU)
and  all  pixels  with  density  below  this  value  will  be  clas-
sified  as  emphysema  and  compared  in  percentage  to  the
entire  lung  parenchyma  volume.  The  percentile  method
quantifies  the  emphysema  through  the  cut-off  point,  which
defines  a  percentile  datum  from  the  histogram.  For  exam-
ple,  the  10th percentile  density  (PD10)  is  derived  from  a
histogram  recording  the  densities  in  HU  of  all  lung  voxels  and
is  defined  as  the  threshold  value  for  which  10%  of  all  lung
voxels  have  a  lower  density.  As  a  true  density  measure  this
value  will  decrease  as  emphysema  worsens.  In  the  average
density  method,  the  average  pulmonary  parenchyma  den-
sity  is  calculated,  which  will  be  lower  as  the  emphysema
progresses.124
Lung  attenuation  values  (in  HU)  can  be  converted  to  lung
tissue  density  values  (g/l)  by  adding  1000  to  the  HU.  For
example,  a  15th percentile  density  value  of  -950  HU  equals  a
lung  density  of  50  g/l,  meaning  that  15%  of  the  pixels/voxels
have  a  density  value  below  50  g/l.125
In  chest  CT,  other  changes  besides  the  emphysema  may
be  seen,  such  as  the  thickening  of  the  bronchial  walls
and  bronchiectasis  (25%)  with  a  widening  of  the  bronchial
diameter  at  the  segmental  and  sub-segmental  level.  When
present,  bronchiectasis  are  cylindrical  or  saccular  and  pre-
vail  in  the  lobes  where  emphysema  is  more  extensive.101
Liver  assessment
All  patients  carrying  alleles  leading  to  AAT  accumulation  in
the  liver  (Z,  MMalton,  MDuarte,  SIiyama,  etc.)  must  undergo  an
initial  assessment  of  liver  changes  by  means  of  abdominal
ultrasound  and  serum  tests.76The  serum  liver  assessment  should  include  transami-
nases  (AST  and  ALT)  as  well  as  alkaline  phosphatase,  GGT,
bilirubin,  albumin,  coagulation  tests,  platelets,  fat  sol-
uble  enzymes,  and  alpha-fetoprotein.76,79 An  abdominal
t
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ltrasound  will  evaluate  liver  changes  --  steatosis,  portal
ypertension,  and  cirrhosis  --  and  the  presence  of  hepato-
ellular  carcinoma.76 FibroscanTM,  a  noninvasive  technique
sing  a  probe  with  an  ultrasound  transducer  and  a  mechan-
cal  vibrating  device,  exerts  dynamic  stress  on  the  body
urface  to  generate  shear  waves.  The  shear  wave  velocity
an  then  be  converted  into  liver  stiffness,  which  is  expressed
n  kilopascals.  It  may  be  used  as  an  alternative  to  ultrasound
o  assess  steatosis  and  liver  fibrosis  in  patients  with  AATD.126
Liver  biopsy  should  not  be  used  for  diagnosis,  since  the
athological  changes  vary  and  are  not  specific.  The  diagnos-
ic  method  should  be  phenotyping  or  genotyping.  However,
iver  biopsy  may  be  indicated  in  certain  cases,  particularly
hen  it  becomes  necessary  to  assess  the  level  of  liver  dam-
ge,  its  progression,  or  to  investigate  the  presence  of  other
elated  diseases.  There  is  usually  lobe  inflammation,  vari-
ble  hepato-cellular  necrosis,  fibrosis,  cirrhosis,  steatosis,
nd  PAS-positive  diastase-resistant  globules  in  some,  but  not
ll,  hepatocytes.76
KeyPoints: Initial Patient Evaluation
-  Initial  evaluation  of  patients  with  AATD  should
include:  spirometry,  lung  volumes,  DLCO,  arterial
blood  gas,  chest  X-ray,  chest  CT  scan  (with  emphy-
sema  index  analysis  if  available),  6-minute  walk  test
-  In  phenotypes  with  liver  involvement,  liver  func-
tions  tests  and  abdominal  ultrasound  (or  FibroscanTM)
should  be  done.
REATMENT
Research  studies  in  the  1980s  recognised  that  plasma  1-
ntitrypsin  levels  could  be  restored  by  intravenous  infusions
f  purified  human  protein.  Initial  licensing  of  augmentation
herapy  in  1987  was  based  upon  an  assumption  that  its  suc-
ess  in  boosting  circulating  and  lung  levels  of  1-AT  would
e  of  clinically  meaningful  benefit  and  a  logical  approach
o  long-term  medical  treatment.  This  assumption  has  sub-
equently  been  explored,  and  robust  demonstration  of  such
utcomes  has  proven  problematic  in  trials  (sensitive  mea-
ures  of  lung  destruction  v.  clinical  efficacy)].127,128
Several  scientific  societies  recommend,  based  on  the
vailable  clinical  evidence,  the  use  of  augmentation  ther-
py,  although  with  some  differences  in  the  indications  for
reatment  as  a  result  of  the  evaluation  of  clinical  studies  and
ate  of  publication.  Based  on  a  study  published  in  2003129
n  the  cost-effective  assessment  of  treatment,  the  revised
RS  guidelines,127 report  a  large  increase  in  costs  for  rela-
ively  little  increase  in  maintaining  patient  quality  of  life.
oreover,  ERS  guidelines  also  highlight  that  fact  that  the
ost-benefit  implications  of  the  apparent  reduction  in  exac-
rbation  frequency  and  severity  remain  to  be  quantified.127In  Portugal,  health  authorities  recognize  the  impor-
ance  of  patients  to  have  access  to  augmentation  therapy;
owever,  the  appreciation  of  medical  evidence  supporting
he  efficacy  of  this  therapy  by  different  prescribers  and
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edical  centres  is  still  under  discussion  and  may  vary,  caus-
ng  inequalities  in  terms  of  clinical  requirements  for  the
pproval  of  the  therapy.
UGMENTATION  THERAPY  WITH  AAT
International  expert  treatment  guidelines  indicate  that
ptimal  management  of  Alpha  -1  should  include  strict
ifestyle  standards,  including  smoking  cessation,  exercise,
iet  and  symptomatic  treatment  with  regular  review  with
ugmentation  therapy  intended  to  slow  down  progression
nd  increase  the  chances  of  preventing  irreversible  tissue
amage].130
The  augmentation  therapy  available  for  AATD  consists
f  the  administration  of  an  intravenous  infusion  of  purified
uman  AAT  extracted  from  a  pool  of  donor  plasma.  The  main
ationale  for  this  therapy  is  to  modify  the  course  of  the  dis-
ase  by  preventing  progression  of  the  emphysema,  reducing
he  number  of  exacerbations,  and  improving  quality  of  life.
n  1990,  the  observation  that  non-smoking  individuals  with
Z  phenotype  showed  a  low  risk  of  developing  pulmonary
isease  led  to  the  general  acceptance  that  AAT  serum  levels
ound  in  these  individuals  could  represent  a  minimum  pro-
ective  threshold.131 Later,  Campbell132 demonstrated  that
he  mean  area  of  damage  exerted  by  neutrophils  was  unre-
ated  to  AAT  concentration,  until  its  level  dropped  below
0  M.  Since  then,  the  target  for  circulating  AAT  to  give
roper  lung  protection  has  been  widely  accepted  to  be  11  M
57  mg/dl  as  determined  by  nephelometry).
The  grounds  for  using  AAT  in  the  treatment  of  pulmonary
isease  are  based  on  its  biochemical  role  and  clinical  effi-
acy.  Its  intravenous  administration  resulted  in  an  increment
f  AAT  serum  level  above  the  protective  threshold,  increased
oncentration  in  the  alveolar  lining  fluid,  and  neutralised
ctivity  of  the  serum  and  alveolar  elastase  from  neutrophils
hroughout  the  interval  between  doses.133--136 A  decrease  in
he  degradation  of  elastase  has  also  been  shown  through
he  quantification  of  serum,  urinary  and  alveolar  lining  fluid
evels  of  desmosine  and  isodesmosine  markers.137,138
Stockley  demonstrated  a  decrease  in  leukotriene  B4
LTB4),  myeloperoxidase  (MPO)  and  interleukin  8  (IL8),
lbeit  only  significantly  reduced  in  patients  undergoing  AAT
ugmentation  therapy.136
Clinical  efficacy  should  address  the  following  questions:
oes  AAT  augmentation  therapy  have  a  positive  effect  in
owering  the  decline  of  pulmonary  function  and  in  delay-
ng  the  progression  of  emphysema?  Does  it  decrease  the
umber  and  severity  of  exacerbations?  Does  it  improve  func-
ional  capacity,  patient  symptoms  and  survival?  Is  it  safe
nd  cost-effective?8 Hence,  medical  grounds  are  based  on
he  results  of  various  studies  with  different  designs  (obser-
ational  or  randomized  and  placebo-controlled)  comparing
he  decline  in  pulmonary  function,  variation  of  lung  density
ssessed  by  chest  CT,  mortality  rate,  frequency  and  severity
f  exacerbations,  impact  on  the  quality  of  life  and  functional
apacity  between  groups  of  patients  submitted  to  therapy
nd  patients  who  have  not  been  treated.  Among  these,  the
andomized  studies  controlled  with  placebo  stand  out,  since
hey  have  demonstrated  a  smaller  loss  in  lung  density  quan-
ified  by  CT  in  subjects  that  have  been  submitted  to  AAT
p
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herapy.  Table  5  summarizes  the  main  results  for  studies
upporting  the  use  of  the  AAT  therapy.
electing  candidates  --  treatment  criteria
ge  --  the  age  range  for  starting  treatment  is  unknown;  how-
ver,  most  patients  are  expected  to  be  in  the  fourth  decade
f  life  when  diagnosed,  since  the  emphysema  usually  devel-
ps  approximately  ten  years  earlier  than  in  smoking-related
OPD.  The  minimal  age  for  initiating  therapy  is  18  and  any
xception  must  be  justified.  The  maximum  age  limit  may  be
stablished  depending  on  each  case.  Table  6
Genotype  -  pulmonary  disease  in  AATD  is  associated  with
enotypes  such  as  ZZ,  ZQ0,  Q0Q0,  and  other  combinations
ith  rare  deficient  or  null  variants.  The  clinical  efficacy  of
he  AAT  therapy  is  better  documented  in  the  treatment  of
Z  patients.
Importantly,  knowing  that  approximately  10%  of  patients
ith  SZ  genotype  have  a  serum  level  below  the  protective
hreshold,  it  seems  acceptable  to  include  these  subjects,  as
ong  as  all  other  criteria  for  therapy  are  verified.  However,
or  SZ  individuals  there  is  no  scientific  evidence  supporting
linical  efficacy  of  the  therapy.
AAT  Level  --  Decisional  cut-off  -  Patients  with  serum  levels
 57  mg/dl  (nephelometry)  are  candidates  for  AAT  replace-
ent  therapy.  Table  7
Pulmonary  Functional  assessment  and  CT  Densitometry
Observational  studies  indicate  a  smaller  decline  in
ulmonary  function  of  patients  undergoing  therapy  with
irways  obstruction  within  FEV1 31-65%  or  FEV1 35-49%  of
redicted  values.  Patients  with  more  severe  obstructions  do
ot  appear  to  have  benefitted  from  therapy.67,139 A  study
arried  out  in  2009  and  comprising  164  patients,  concluded
hat  a  beneficial  effect  was  observed  in  the  group  of  ex-
mokers  with  FEV1 <  50%  predicted  value.141 Furthermore,
n  a  meta-analysis  that  included  five  clinical  trials  and  1509
atients  undergoing  therapy  vs.  controlled  patients,  the
reated  group  registered  a  lower  functional  decline  with  this
esult  showing  greater  significance  in  the  group  of  patients
ith  FEV1 between  30-65%  of  predicted  value.145
The  analysis  of  these  studies  suggests  that  the  decline
n  FEV1 is  not  linear  and  drops  faster  in  the  moderate
bstruction  interval.150 Nevertheless,  Wencker140 carried
ut  a multi-centre  and  retrospective  study  to  assess  the
rogress  of  emphysema  before  and  during  the  AAT  therapy
assessment  of  the  47  months  prior  and  the  50  months  dur-
ng  therapy  --  in  the  60  mg/Kg/week  dose),  which  included
6  patients  split  into  three  functional  groups  --  FEV1 <  30%,
etween  30-65%  and  >  65%,  and  they  verified  the  existence
f  patients  with  severe  deficiency,  preserved  pulmonary
unction  (FEV1 >  65%)  and  fast  declining  pulmonary  func-
ion  (>  120  ml/year).  Moreover,  in  this  latter  group,  the
oss  of  pulmonary  function  prior  and  during  treatment  was
55  ±  70.4  and  52.7  ±  61.3  ml,  respectively  and  according
o  these  authors,  an  early  implementation  of  AAT  therapy
ignificantly  reduced  patient  decline  of  respiratory  function.
More  recently,  randomized  studies  controlled  with
lacebo,  in  which  the  emphysema  progression  is  quanti-
ed  by  CT  scans,  have  proposed  this  technology  as  the  best
ndicator  of  the  efficiency  of  this  therapy.  The  authors  find
hat  CT  densitometry  is  more  sensitive  than  the  variation  of
Portuguese  consensus  document  for  the  management  of  alpha-1-antitrypsin  deficiency  13
Table  5  Studies  carried  out  over  the  years  to  evaluate  efficacy  of  AAT  augmentation  therapy.
Authors  Dose  Type  of  Study  Primary  Endpoint  Results
Seersholm  et  al.
(1997)139
60  mg/Kg/week  Observational  with
controlled  group
n =  295
FEV1 decline  Lower  FEV1 decline  in  the
group  treated.  Significant
effect  only  for  the  group
with  FEV1 31-65%  of
predicted  value  (p  =  0.04)
American AAT
Deficiency  Registry
Study  Group  (1998)67
33%  weekly  43%  every
two  weeks
24%  monthly
Observational  with
controlled  group
n =  1129
FEV1 decline
Mortality
Lower  FEV1 decline  in  the
treated  group  with  FEV1
35-49%  of  predicted  value
(p  =  0.03)
Reduced  mortality  in  36%  at
60  months  (p  =  0.02)
Wencker et  al.
(2001)140
60  mg/Kg/week  Observational
without  controlled
group  (before  vs.
after  therapy)
n  =  96  (3  groups  FEV1
<  30%,  FEV1 30-65%,
and  FEV1 >  65%)
FEV1 decline  Lower  FEV1 decline  during
treatment  period;  in  the
whole  group  49.2  vs.  34.2
ml/year  (p  =  0.019).
Significant  effect  in  a  small
group  (n  =  7)  of  rapid
decliners  with  FEV1 >  65%
(256  vs.  53  ml/yr.  P  =  0.001)
Tonelli et  al.
(2009)141
60  mg/Kg/  week  Observational  with
controlled  group
(n  =  164)
FEV1 decline
Mortality
Significant  effect  in  the
group  treated  (+10.6  ±  21.4
vs.  -  36.96  ±  12.1  ml/year;
p =  0.05)
Beneficial  effect  in  the
group  with  initial  FEV1 <  50%
of predicted  value  and  in
former  smokers
Mortality  -  NS
Dirksen et  al.
(1999)142
250  mg/Kg/month
(for  at  least  three
years)
RCT
n  =  56  (ZZ)
FEV1 30-80%
predicted  value
FEV1 decline
Secondary  endpoint:
Lung  density
Vital  Capacity
DLCO
FEV1 decline  overlaps  in
both  groups
(26.5  ±  15.1  vs.
25.2  ±  22.0ml/year)  p  =  0.96
Tendency  for  a  reduced  loss
of lung  density  in  the
treated  group  (p  =  0.07)
Vital  Capacity  and  DLCO  -
NS
Dirksen et  al.
(2009)143
EXACTLE  trial
60  mg/Kg/week
Week
RCT
n  =  77  (FEV1 25-80%)
(2-2.5  years)
Lung  density
Secondary  endpoint:
Pulmonary  function
Exacerbations
Quality  of  life
Reduced  loss  of  lung  density
in  the  treated  group
(p  =  0.49)
FEV1 and  DLCO  -  NS
Number  of  exacerbations  -
NS  (2.55  v.  2.19;  p  =  0.265;
less  serious  in  the  treated
group)
SGRQ  -  NS  (1.48  vs.  2.37)
p =  0.695
Stockley et  al.
(2010)144
250  mg/Kg/month
(n  =  56)  60
mg/Kg/week  (n  =  77)
Meta-analysis  (of
both  Dirksen  studies)
Lung  density
FEV1 decline
Reduced  loss  of  lung  density
in  the  treated  group
(p  =  0.006)
(mean  change  from  baseline
-4.082  vs.  -6.379  g/L  with  a
treatment  difference  of
2.297  (95%  CI  0.669-3.926)
FEV1 decline  -  NS
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Table  5  (Continued)
Authors  Dose  Type  of  Study  Primary  Endpoint  Results
Chapman  et  al.
(2009)145
60  mg/Kg/week
(n =  391)  250
mg/Kg/month  (n  =  56)
AAT  at  dosage
determined  by
patients’  managing
physicians  (n  =  1062)
Meta-analysis  -five
studies  (n  =  1509
treated  patients  vs.
control)
FEV1 decline  Lower  FEV1 decline,
particularly  in  the  group
with  FEV1 30-65%  of
predicted  value
Gotzsche et  al.
(2010)146
60  mg/Kg/week  Cochrane
meta-analysis  -  two
random  studies
(n  =  140)
FEV1 decline  and
DLCO
Lung  density
Exacerbations
No  differences  in  the
pulmonary  function
Reduced  loss  of  lung  density
in  the  treated  group
No  differences  in  the
exacerbations
Chapman
et al.(2015)147
RAPID  trial
60  mg  /Kg/week  RCT
n  =  180  (FEV1 35-70%)
-  two  years
Lung  density  assessed
at TLC  and  FRC
Reduced  loss  of  lung  density
at  TLC,  in  the  treated  group
Barros-Tizón  et  al.
(2012)148
180  mg/Kg/  21  days  Retrospective  study
(before  and  after
therapy)
Number  and  severity
of exacerbations
Cost  of  admissions
Reduced  number,  severity,
and cost  of  post-treatment
admissions
Lieberman (2000)149 55%  weekly,  37%
every  two  weeks,  8%
monthly
Observational
(internet  survey)
(n  =  89)
Frequency  of
exacerbations
Decrease  in  3-5/year  to
0-1/year  after  starting
therapy
Abbreviations: RCT, randomized controlled trial; NS, non-significant
Table  6  Criteria  for  augmentation  therapy.
Non-smokers  or  ex-smokers  (≥  6  months)
Age  ≥  18
COPD  diagnosis  (FEV1/FVC  <  70  postbronchodilator)
attributed  to  emphysema  caused  by  AAT  deficiency
Serum  level  of  AAT  ≤  57  mg/dl
No selective  immunoglobulin  A  deficiency
FEV1 30-70%  of  predicted  value
FEV1 >  70%  in  the  case  of  rapid  decliner  (decrease  >  120
ml/year)
Individual  decision  in  other  cases
Augmentation  therapy  should  not  be  discontinued  in  case
of pulmonary  function  deterioration,  even  if  it  reaches
the  lower  established  limit  for  its  initiation
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Table  7  Procedures  before  initiating  therapy.
Complete  liver  function  tests  and  liver  ultrasound
Serum  immunoglobulin  tests
Hepatitis  (B  and  C)  and  acquired  human  immunodeficiency
virus serologies
Hepatitis  B  vaccination
Pulmonary  Function  Testing  -  Spirometry,  Pulmonary
Volumes,  and  Carbon  Monoxide  Diffusing  Capacity
Arterial  blood  gas  analysis  and  6-minute  walk  test
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density  as  a  primary  endpoint  and  included  180  patientsPanniculitis: Consider treatment if recurrent and low ATT serum
level
hysiological  indicators  or  quality  of  life143 as  there  may  be
oss  of  lung  density  with  stable  FEV1 values.150 In  an  ini-
ial  study,  which  had  as  its  primary  outcome  the  assessment
f  the  FEV1 decline,  56  patients  with  FEV1 between  30-80%
ere  randomised  for  a  dose  of  250  mg/Kg/4  weeks,  for  three
ears.  No  significant  difference  in  the  decline  of  the  pul-
onary  function  was  detected  between  patients  although
here  was  a  tendency  for  a  reduced  loss  of  lung  density  in
he  active  treatment  group.142
The  EXACTLE  study143 lasted  for  24-30  months  and
ncluded  77  patients  with  postbronchodilator  FEV between1
5-80%  for  the  dose  of  60  mg/Kg/week  vs.  placebo.  The
ndpoint  goal  of  this  study  was  to  analyse  the  loss  of  lung
ensity  by  CT  measures.  A  marginal  statistical  significance
w
a
a
High resolution  chest  CT  and  assessment  of  lung  density  (if
available)
as  observed  in  only  one  of  the  four  analyses  performed
upporting  the  AAT  treatment  as  beneficial.  Another  objec-
ive  of  EXACTLE  was  to  evaluate  the  frequency  and  severity
f  exacerbations  among  groups  of  patients.  Only  the  num-
er  of  hospital  admissions  for  exacerbation  was  lower  in
he  AAT  treated  group  due  to  a reduction  in  exacerbation
everity.  In  addition,  there  was  also  found  a  correlation
etween  the  decline  of  pulmonary  function  and  the  decline
f  lung  density,  despite  no  difference  being  observed  in
he  functional  decline  rate  between  groups.  An  integrated
ssessment  of  the  findings  in  these  two  studies  showed  a  sig-
ificant  reduction  in  the  decline  of  lung  density  in  treated
atients,  where  -2.297  g/L  (p  =  0.006)  difference  was  found
etween  groups.144
The  RAPID  study,147 which  used  the  analysis  of  lungith  FEV1 between  35-70%,  showed  that  augmentation  ther-
py  contributes  to  the  preservation  of  lung  density  when
ssessed  in  terms  of  TLC.  This  study  lasted  two  years  and
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Portuguese  consensus  document  for  the  management  of  alp
patients  were  split  into  two  groups  (active  treatment  group
--  AAT  at  the  dose  of  60  mg/Kg/week  vs.  placebo).  Lung
density  loss  of  1.45  g/L/year  was  observed  in  the  treated
group  vs.  2.19  g/L/year  in  the  placebo  group  with  significant
difference  (p  =  0.03).  However,  no  differences  were  found
between  the  groups  in  terms  of  FEV1,  carbon  monoxide
diffusing  capacity,  results  on  the  shuttle  test,  and  health-
related  quality  of  life  improvement.  This  study  also  specified
that  treatment  benefits  were  dose-related  and  more  expres-
sive  in  patients  with  higher  serum  trough  AAT  concentration.
The  dose  of  60  mg/Kg/week  was  not  established  as  an
optimal  dose.  Higher  trough  concentrations  were  achieved
during  treatment  in  heavier  patients  with  greater  AAT  con-
centrations  in  pre-treatment.147
An  open  label  period  followed  (RAPID  Extension-2  years),
showing  that  when  patients  of  the  placebo  group  began
treatment  with  AAT,  their  lung  density  decline  rate  would
overlap  that  of  the  actively  treated  group  although  the  lost
density  would  not  be  recovered,  which  suggested  a  need  for
early  treatment.  However,  the  authors  stated  that  they  did
not  know  whether  the  preservation  of  lung  density  or  struc-
ture  was  uniform  to  all  deficient  patients  or  in  every  stage
of  the  disease.147
The  results  of  these  three  studies  described  above,  which
included  mostly  ZZ  patients,  were  presented  without  dis-
crimination  of  any  functional  subgroup  where  the  decrease
in  lung  density  decline  rate  could  have  been  slower;  there-
fore  leaving  the  impression  that  those  patients  with  FEV1
in  the  established  intervals  for  the  studies  (FEV1 between
25/30/35  --  70/80%  of  predicted  value)  would  benefit  from
the  AAT  therapy.  The  ATS/ERS  document28 provides  the  pos-
sibility  of  treating  patients  with  an  almost  normal  pulmonary
function  as  long  as  they  are  identified  as  rapid  decliners  and
the  Canadian151 and  Spanish  Pneumology  Societies110 recom-
mend,  respectively,  AAT  treatment  for  patients  with  FEV1
between  25-80%  and  FEV1 <  80%  of  predicted  value.
This  controversy  regarding  treatment  of  patients  with
FEV1 >65%  was  approached  in  a  review  article  published  by
Teschler  in  March  2015  with  the  recommendation  based  on
the  author’s  experience  to  functionally  assess  these  patients
every  six  months.  Rapid  decliners  may  initiate  therapy
although  this  is  an  individual  decision.152
In  brief,  the  collected  evidence  points  towards  AAT
therapy  being  efficient  in  preserving  lung  density  although
there  are  no  significant  results  regarding  other  indicators,
such  as  health-related  quality  of  life  and/or  exacerbations.
Regarding  functional  decline,  results  are  contradictory,  with
some  observational  studies  and  a  meta-analysis  suggesting
a  smaller  decline  in  the  group  of  patients  with  moderate
bronchial  obstruction.  Randomized  studies  did  not  find  a
significant  difference  in  the  FEV1 decline  rate  between  the
treatment  group  and  the  placebo  group.  In  relation  to  other
indicators  studied  such  as  mortality,  the  American  Registry67
has  revealed  a  reduction  in  the  group  of  treated  patients
with  FEV1 <  50%  while  the  study  led  by  Tonelli141 did  not  show
any  differences  between  the  two  groups.
Taking  into  account  all  these  data,  the  Portuguese  study
group  of  AATD  reached  an  agreement  to  recommend  AAT
augmentation  therapy  be  provided  to  all  patients  with  FEV1
between  30-70%  of  predicted  value  or,  if  higher,  in  the  case
of  a  rapid  decline.  Concerning  treatment  of  liver  disease,
the  augmentation  therapy  is  only  indicated  in  subjects  with
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oncomitant  pulmonary  involvement.  In  other  cases  only
reventive  measures  are  available  (vaccination  anti-A  and
 hepatitis,  elimination  of  alcohol  and  other  hepatotoxic
gents).153 Still,  AAT  augmentation  therapy  may  be  indicated
or  the  treatment  of  necrotising  panniculitis  due  to  its  effi-
acy  in  some  clinical  cases  and  in  the  prevention  or  control
f  skin  lesions  related  to  this  disease.154,155
Selective  immunoglobulin  A  (IgA)  deficiency  is  a  con-
raindication  to  treatment  as  augmentation  therapy  may
ontain  small  amounts  of  IgA.  Hypersensitive  or  anaphylac-
ic  reactions  with  anti-IgA  antibodies  may  occur  in  these
atients,  therefore,  testing  for  this  deficiency  is  recom-
ended  before  initiating  therapy.156
THER  THERAPIES
ung  volume  reduction  surgery  in  patients  with  severe  pul-
onary  emphysema  has  shown  modest  results  in  terms  of
urvival  and  functional  capacity  in  patients  with  emphysema
ith  upper  lobe  predominance;  experience  with  patients
ith  AATD  is  limited  but  there  seems  to  be  a  tendency
o  greater  mortality  within  this  subgroup.157 Lung  volume
eduction  by  placing  endobronchial  valves  is  an  experimen-
al  intervention  in  patients  with  severe  emphysema  and
ATD  was  an  exclusion  criterion  in  the  biggest  randomized
tudy  published.158,159
Pulmonary  transplantation  is  reserved  for  patients  with
o  other  choice  of  therapy  and  the  Portuguese  group  is  fol-
owing  the  current  international  recommendations.  AATD  is
n  indication  for  transplantation  in  about  5.8%  of  cases.
atients  with  no  contraindications  and  a BODE  index  >5  may
e  referred  to  a  pre-transplant  consultation.  Indications  for
ombined  liver  and  lung  transplantation  are  rare  but  may
e  considered  when  there  is  documented  cirrhosis  in  biopsy
nd  a  portal  gradient  > 10  mmHg160,161.  There  is  no  evidence
or  recommending  augmentation  therapy  after  pulmonary
ransplantation;  although  some  authors  recommend  consid-
ring  it  in  case  of  infection  or  acute  rejection.  In  selected
ases  with  accelerated  functional  deterioration  one  might
onsider  restarting  augmentation  therapy  and  maintaining
t  based  on  results.152,156
VAILABLE FORMULATIONS
he  following  formulations  are  currently  available  in  Portu-
al:  Prolastin® and  Respreeza®.162
Dosage  plans:  The  current  plan  approved  by  the  FDA
Food  and  Drugs  Administration)  is  weekly  administration
60  mg/Kg),  since  it  was  one  of  the  first  to  be  proposed,  the
ne  analysed  the  most,  and  recommended  by  ATS/ERS.28,79
owever,  for  the  sake  of  cost  reduction  and  convenience
or  the  patient,  other  dosages  have  been  studied  but  with
o  formal  recommendation  for  any  change  in  dose  or
dministration  interval.  The  doses  of  50  mg/kg/7  days  and
20  mg/kg/14  days  have  appeared  to  maintain  Cmin higher
han  those  considered  as  protective  in  90%  of  patients.163--166he  dose  of  180  mg/Kg/21  days  is  able  to  maintain  a  protec-
ive  Cmin for  85%  of  the  time  between  doses.163,166 Hubbard
nd  Dirksen  studied  monthly  dosages,  where  250  mg/kg  of
AT  was  administered  with  serum  levels  and  anti-elastase
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ctivity  showing  values  considered  as  protective  for  28  days
ollowing  infusion.135,142
Efficacy  and  safety:  Experience  with  augmentation  ther-
py  suggests  that  it  generally  is  safe,  well  tolerated  and
ith  very  few  adverse  effects.  In  the  study  carried  out  by
encker,  who  followed  443  patients  over  the  course  of  six
ears,  it  was  noted  that  86%  of  patients  did  not  have  any
dverse  reactions  and  the  following  were  the  most  com-
on  effects  reported:  nausea  and  vomiting  (4.7%),  hives
4.1%),  fever  (3.8%),  dyspnoea  (3.8%)  and  anaphylactic  reac-
ion  (0.9%).167 In  the  study  carried  out  by  Stoller,  with  747
atients  over  the  course  of  seven  years,  it  was  noted  that
3%  of  patients  did  not  have  any  adverse  reactions.  The
ost  common  adverse  effects  were  headaches  (47%),  dizzi-
ess  (17%),  nausea  (9%),  and  dyspnoea  (9%).168 Taking  into
ccount  the  fact  that  this  product  is  derived  from  human
lasma,  there  appears  to  be  no  case  where  prior  disease,
uman  immunodeficiency  virus  (HIV),  viral  hepatitis,  or
he  development  of  viral  antibodies  were  transmitted.133,169
t  should  be  noted  that  the  studies  have  shown  a  lower
ate  of  adverse  effects  in  patients  who  were  submitted  to
onthly  therapy  than  those  who  were  submitted  to  weekly
herapy.169
AAT  administration  by  aerosol  may  be  a  promising  option
mong  the  several  therapy  alternatives  being  studied.  It
s  immediately  directed  to  the  target  (lung)  bypassing  the
hort  plasma  half  life  limitations.  Assuming  that  smaller
uantities  of  the  drug  may  be  required,  therapy  by  aerosol
ay  be  cheaper  in  addition  to  allowing  self-administration
nd  enabling  production  of  large  quantities  with  no  risk  of
iral  contamination.150
ATIENT FOLLOW-UP
ATD  patient  follow-up  may  be  considered  on  two  levels:
efore  and  after  initiating  replacement  therapy.  Individu-
ls  who  were  diagnosed  in  their  childhood  may  never  have
ny  complaints  if  they  never  smoke.  A  respiratory  func-
ional  assessment  is  suggested  at  the  end  of  adolescence  and
fterwards  at  2-3  year  intervals.  Data  on  the  decline  of  the
ulmonary  function  will  always  be  useful  for  comparison  pur-
oses  in  case  of  eventually  initiating  therapy.170 In  the  case
f  patients  with  no  criteria  for  initiating  therapy  at  the  time
f  diagnosis  --  AAT  concentration  below  the  recommended
hreshold  with  no  functional  criteria  --, follow-up  should
onsist  of  spirometry  every  semester,  annual  assessment  of
iver  function  and  chest  CT  with  emphysema  quantification
if  available),  without  prejudice  for  individual  decision  at
ll  times.152
The  follow-up  of  patients  undergoing  augmentation  ther-
py  should  include79,156:  spirometry  with  bronchodilator  test
very  semester;  plethysmography  and  the  study  of  carbon
onoxide  diffusion  capacity  once  a  year.  Although  ERS/ATS
nd  SEPAR  recommend  an  annual  assessment  of  liver  func-
ion,  an  efficient  screening  of  liver  disease  will  imply  blood
ests  --  complete  blood  count,  liver  enzymes  --  and  abdomi-
al  ultrasound.  In  the  case  of  individuals  with  an  established
iver  disease,  ultrasound,  liver  function,  and  dosage  of
lpha-fetoprotein  should  be  repeated  at  regular  intervals
very  six  to  12  months.171 High  resolution  chest  tomogra-
hy  is  not  recommended  in  follow-up  although  it  may  be
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epeated  in  order  to  clarify  any  complications.  Lung  density
easurements  will  be  of  particular  interest  within  the  scope
f  medical  research.  Hence,  assessment  before  replacement
ill  mostly  be  of  pulmonary  function  although  later  CT  with
ensitometry  appears  to  be  the  most  sensitive  indicator  for
ssessing  benefits  to  the  patient.
Key points
1.  In  the  therapeutic  approach  of  patients  with
emphysema  due  to  AATD,  international  COPD  rec-
ommendations  should  be  followed  for  smoking
cessation,  symptomatic  treatment,  referral  to  res-
piratory  rehabilitation  programmes,  exercise,  diet,
and  vaccination.
2.  Recent  studies  have  shown  clinical  efficacy  of  aug-
mentation  therapy  in  preserving  pulmonary  density,
quantified  by  CT.
3.  Criteria  for  augmentation  therapy  are:  age  ≥  18;
non-smokers  or  ex-smokers  (≥  6  months);  AAT
≤  57  mg/dl  (nephelometry);  deficient  phenotypes
(ZZ,  ZQ0,  Q0Q0,  SZ,  or  other  allele  combinations
with  rare  variants);  COPD  diagnosis  (FEV1/FVC  <  70)
attributed  to  emphysema  caused  by  AAT  deficiency
and  FEV1 postbronchodilator  between  30-70%  of
that  predicted;  no  immunoglobulin  A  deficiency;
augmentation  therapy  is  not  indicated  in  liver  dis-
ease  (if  there  is  no  pulmonary  involvement),  and  it
may  be  considered  in  panniculitis.
4.  Dose:  60  mg/kg/  week.
5.  AAT  serum  level  testing  is  not  recommended  for
therapeutic  monitoring.
6. Follow-up:  1)  respiratory  monitoring:  spirometry
with  bronchodilator  test  per  semester/year;  annual
plethysmography  and  carbon  monoxide  diffusion
capacity;  chest  CT  --  at  the  initial  diagnosis  and
repeatedly  as  per  medical  indication.  2)  Liver  mon-
itoring:  annual  laboratory  assessment;  abdominal
ultrasound  --  every  6  to  12  months.
7.  Lung  volume  reduction  surgery  is  not  recommended
in  this  group  of  patients
8.  There  are  precise  indications  for  referral  to  pul-
monary  transplantation.
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